Interleukin-2 therapy of cancer.
The aim of this review is to evaluate the results of IL-2 therapy of cancer two decades after the first experiments and to discuss whether and which results of local, systemic and adjuvant IL-2 therapy in preclinical models can be translated into clinics. The attention is also focused on the development and utilization of the IL-2 gene-modified tumour vaccines for therapeutic purposes. The prospects and limitations of both, IL-2 therapy and IL-2 gene therapy are discussed.
Bubeník
J
J
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic. bubenik@img.cas.cz
D015316:Genetic Therapy; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*
D007376:Interleukin-2